Sign In
Buy BMY
$56.60
+1.88 (+3.44%)
At Close: Jun 04, 2026
A Peek Into The Markets: US Stock Futures Down; Apple Tops Q2 Views
09:49am, Friday, 29'th Apr 2022 Benzinga
Pre-open movers
U.S. stock futures traded lower in early pre-market trade after the Dow Jones jumped more than 600 points in the previous session. Investors are awaiting earnings results from Bristol
Bristol Myers Squibb (BMY) Q1 Earnings and Revenues Surpass Estimates
09:47am, Friday, 29'th Apr 2022
Bristol Myers (BMY) delivered earnings and revenue surprises of 2.08% and 3.48%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
7 Stocks To Watch For April 29, 2022
08:33am, Friday, 29'th Apr 2022 Benzinga
Some of the stocks that may grab investor focus today are:
Wall Street expects Bristol-Myers Squibb Company (NYSE: BMY) to report quarterly earnings at $1.91 per share on revenue of $11.36 billion
Bristol Myers Q1 Earnings Surpass Street Expectations, Lowers FY22 Guidance
08:20am, Friday, 29'th Apr 2022
Bristol-Myers Squibb Co (NYSE: BMY) has posted Q1 revenues of $11.65 billion, an increase of 5% Y/Y (7% constant currency), beating the consensus of $11.36 billion. Eliquis, Opdivo, cell therapy p
Bristol Myers 1st-quarter sales up on Eliquis, Opdivo
07:04am, Friday, 29'th Apr 2022
Drugmaker Bristol Myers Squibb posted slightly better-than-expected first-quarter earnings on Friday on growth of sales of its blood thinner Eliquis and cancer drug Opdivo, but said it no longer expec
Drug/Biotech Stocks Q1 Earnings Due on Apr 29: BMY, ABBV, AZN
02:53pm, Thursday, 28'th Apr 2022 Zacks Investment Research
Let us take a look at what is in store for BMY, ABBV, and AZN that are scheduled to report on Apr 29.
Why Bristol-Myers (BMY) Might Surprise This Earnings Season
12:40pm, Thursday, 28'th Apr 2022 Zacks Investment Research
Bristol-Myers (BMY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Drug/Biotech Stocks Q1 Earnings Due on Apr 29: BMY, ABBV, AZN
12:02pm, Thursday, 28'th Apr 2022
Let us take a look at what is in store for BMY, ABBV, and AZN that are scheduled to report on Apr 29.
Why Bristol-Myers (BMY) Might Surprise This Earnings Season
09:49am, Thursday, 28'th Apr 2022
Bristol-Myers (BMY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
What To Expect From Bristol Myers Squibb Stock After Q1 Results?
08:00am, Thursday, 28'th Apr 2022
BMY stock has seen a 23% rise YTD, outperforming its peers and the broader markets, primarily due to an increase in dividends and boosting its share repurchase program.
Bristol-Myers (BMY) to Post Q1 Earnings: Is a Beat in Store?
04:00pm, Wednesday, 27'th Apr 2022 Zacks Investment Research
Bristol-Myers (BMY) Q1 earnings might have gained from strong demand for Eliquis and incremental contribution from newer drugs. Operating expenses might have jumped on broader portfolio-related costs.
Earnings Previews: AbbVie, AstraZeneca, Bristol-Meyers Squibb
12:03pm, Wednesday, 27'th Apr 2022
Between the time markets closed on Tuesday and before they opened again on Wednesday, more than 600 U.S.
Alexandria (ARE) Q1 FFO Beats Estimates, Revenues Rise Y/Y
02:37pm, Tuesday, 26'th Apr 2022 Zacks Investment Research
Alexandria Real Estate's (ARE) reports better-than-anticipated first-quarter 2022 performance attributable to healthy leasing activity and solid internal growth.
After Bristol Myers Cuts Ties, Nektar Implements Cost Restructuring
11:54am, Tuesday, 26'th Apr 2022
Nektar Therapeutics (NASDAQ: NKTR) announced a new strategic plan to prioritize key research and development efforts and cut 70% of its workforce, including several changes to its executive team.
3 Soaring Warren Buffett Stocks You Can Buy for $76 or Less
10:57am, Tuesday, 26'th Apr 2022 The Motley Fool
They aren't the most exciting stocks out there, but these long-term winners have what they need to keep climbing.
